However, in a recent study, we found that the inhibition of the IRE1α/XBP1 axis efficiently reduced the survival of mutp53-carrying Multiple Myeloma (MM) cells [19], encouraging the use of this therapeutic strategy against mutp53-carrying hematological cancers also. Here, XBP1 is linked to hematopoietic and lymphoid cell neoplasm.